H19 and hepatocellular carcinoma: Downregulating the expression of lncRNA H19 lowers the cellular drug accumulation level in human hepatocellular carcinoma (HCC) by enhancing the methylation of the multidrug resistant gene 1 (MDR1) promoter and upregulating p-glycoprotein expression, which ultimately leads to doxorubicin resistance.